ReviewCNS drugs2009
Management of patients presenting with acute psychotic episodes of schizophrenia.
Review in CNS drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.BMC psychiatry · 2013Trial
- Clinical outcomes in first-episode schizophrenia: identifying predictors of relapse.Social psychiatry and psychiatric epidemiology · 2026Article
- Genetic markers of early response to lurasidone in acute schizophrenia.The pharmacogenomics journal · 2025Article
- Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia.Scientific reports · 2025Observational
- Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis.Drugs in context · 2024Review
- Preventative effects of aripiprazole and quetiapine on seizure and lethality in a mice cocaine toxicity model: an experimental study.The Journal of international medical research · 2019Article
- [Acute agitation conditions].Der Nervenarzt · 2015Review
- Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Patient preference and adherence · 2015Article
- Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.AAPS PharmSciTech · 2014Article
- Review
- Medical evaluation and triage of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta medical evaluation workgroup.The western journal of emergency medicine · 2012Article
- Antipsychotic agents: efficacy and safety in schizophrenia.Drug, healthcare and patient safety · 2012Article
- Nonaffective acute psychoses: uncertainties on the way to DSM-V and ICD-11.Current psychiatry reports · 2011Review
- The management of psychiatric emergencies.Deutsches Arzteblatt international · 2011Review
- Patient perspectives on antipsychotic treatments and their association with clinical outcomes.Patient preference and adherence · 2010Article
- Research in people with psychosis risk syndrome: a review of the current evidence and future directions.Journal of child psychology and psychiatry, and allied disciplines · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The initial management of patients with schizophrenia presenting to psychiatric emergency departments with an acute psychotic episode requires rapid decisions to be made by physicians concerning the treatment of individuals who are likely to be relatively uncooperative, agitated and lacking insight. The treatment decision must be adapted to the individual characteristics and needs of each patient. This article reviews the issues from the perspective of the initial management of acute psychosis as it is currently practised in Europe, and discusses the pragmatic implications for initial treatment decisions and the elaboration of a long-term treatment plan. Initially, administration of antipsychotics to control psychotic symptoms and benzodiazepines to control agitation represents the cornerstone of treatment. Oral medication is preferable to injectable forms wherever possible, and atypical antipsychotics are to be preferred over conventional agents because of their lower risk of extrapyramidal adverse effects, which are a major determinant of poor adherence to treatment. Whatever antipsychotic is chosen by the physician during the initial period, it is likely that it will need to be continued for many years, and it is thus important to take into account the long-term safety profile of the drug chosen, particularly in relation to extrapyramidal adverse effects, metabolic complications and quality of life. Building a therapeutic alliance with the patient and his/her family or carers is an important element that should be included in the initial management of psychosis. The long-term goal should be to minimize the risk of psychotic relapse through adequate treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.